Extended Data Fig. 9: Validations of altered oligodendrocyte heterogeneity in MS and mRNA expression differences in lesions.
From: Altered human oligodendrocyte heterogeneity in multiple sclerosis
a, Quantification of BaseScope in situ hybridization of CDH20 in individual patients with MS (corresponds to Fig. 4c) shows an enrichment in chronic inactive lesions in each individual (n = individual number of quantified fields per patient (n = 7): MS235: n = 10 for active and chronic inactive lesions, MS200: n = 4 for active, and chronic inactive and chronic active lesions, MS249: n = 4 for active and n = 8 for chronic inactive lesions, MS361: n = 7 for active and n = 10 for chronic inactive lesions, MS106: n = 11 for chronic active and chronic inactive lesions, MS161: n = 6 for chronic active and n = 10 for chronic inactive lesions, MS300: n = 7 for active and n = 10 for chronic inactive lesions. Data are mean ± s.e.m. b, c, BaseScope in situ hybridization of WWOX mRNA shows depletion of detected mRNA in chronic active lesions on average (b) and in individual patients with MS (c). Scale bars, 2 mm (left panel) and 20 µm (middle/right panel). In b, n = 2 for active lesions and n = 4 for chronic inactive and chronic active lesions, in c, dots display the individual number of quantified fields per patient (n = 5), MS245: n = 8 for active, n = 10 for chronic inactive and n = 9 for chronic active lesions, MS361: n = 6 for active and n = 10 for chronic inactive lesions, MS101: n = 6 for chronic inactive and n = 11 for chronic active lesions, MS161: n = 10 for chronic inactive and n = 7 for chronic active lesions, MS296: n = 11 for chronic active and n = 6 for chronic inactive lesions. Data are mean ± s.e.m. P values determined by ANOVA. d, Dot plot of the total normalized RNA UMI counts found within the lesions, NAWM and controls, in which both size and colour indicate z-scores. Blue and large denote low scores; red and large denote high scores; small denotes intermediate scores. e, Density histograms showing the difference in distribution of normalized counts observed between control and remyelinated lesions.
